A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings

Vaccine

Volumn 30, Issue 22, 2012, Pages 3304-3310

  Miyasaka, Tomomitsu ^a   Aoyagi, Tetsuji ^a   Uchiyama, Binei ^b,f   Oishi, Kazunori ^c   Nakayama, Toshinori ^d   Kinjo, Yuki ^e   Miyazaki, Yoshitsugu ^e   Kunishima, Hiroyuki ^a   Hirakata, Yoichi ^a   Kaku, Mitsuo ^a   Kawakami, Kazuyoshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Katta General Hospital   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f Miyagi Cardiovascular and Respiratory Center ^*  (Japan)

Author keywords

Antibody production; NKT cells; Pneumococcal polysaccharide vaccine

Indexed keywords

CD56 ANTIGEN; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, CD; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PNEUMOCOCCAL VACCINES; T-LYMPHOCYTES;

EID: 84859823598     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.007     Document Type: Article

References (34)

1. Butler J.C. Epidemiology of pneumococcal disease. The pneumococcus 2004, 148-168. ASM Press, Washington, DC. 1st ed. E.I. Tuomanen, T.J. Mitchell, D.A. Morrison, B.G. Spratt (Eds.).
2. Filice G.A. Pneumococcal vaccines and public health policy. Consequences of missed opportunities. Arch Intern Med 1990, 150(7):1373-1375.
3. Bennett N.M., Buffington J., LaForce F.M. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 1992, 82(11):1513-1516.
4. Hofmann J., Cetron M.S., Farley M.M., Baughman W.S., Facklam R.R., Elliott J.A., et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333(8):481-486.
5. Plouffe J.F., Breiman R.F., Facklam R.R. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996, 275(3):194-198.
6. Ishida T., Hashimoto T., Arita M., Ito I., Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest 1998, 114(6):1588-1593.
7. Centers for Disease Control and Prevention (CDC) Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009, 58(38):1071-1074.
8. Hussell T., Wissinger E., Goulding J. Bacterial complications during pandemic influenza infection. Future Microbiol 2009, 4(3):269-272.
9. O'Brien K.L., Walters M.I., Sellman J., Quinlisk P., Regnery H., Schwartz B., et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000, 30(5):784-789.
10. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198(7):962-970.
11. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-8):1-24.
12. Mond J.J., Lees A., Snapper C.M. T cell-independent antigens type 2. Annu Rev Immunol 1995, 13:655-692.
13. Snapper C.M., Mond J.J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 1996, 157(6):2229-2233.
14. Vos Q., Lees A., Wu Z.Q., Snapper C.M., Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000, 176:154-170.
15. Barrett D.J., Ayoub E.M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986, 63(1):127-134.
16. Snapper C.M., McIntyre T.M., Mandler R., Pecanha L.M., Finkelman F.D., Lees A., et al. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med 1992, 175(5):1367-1371.
17. Bendelac A., Rivera M.N., Park S.H., Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997, 15:535-562.
18. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4(3):231-237.
19. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278(5343):1626-1629.
20. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000, 192(5):741-754.
21. Liu T.Y., Uemura Y., Suzuki M., Narita Y., Hirata S., Ohyama H., et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 2008, 38(4):1012-1023.
22. Hammond K.J., Pellicci D.G., Poulton L.D., Naidenko O.V., Scalzo A.A., Baxter A.G., et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001, 167(3):1164-1173.
23. Rogers P.R., Matsumoto A., Naidenko O., Kronenberg M., Mikayama T., Kato S. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods 2004, 285(2):197-214.
24. Kawakami K., Yamamoto N., Kinjo Y., Miyagi K., Nakasone C., Uezu K., et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 2003, 33(12):3322-3330.
25. Kobrynski L.J., Sousa A.O., Nahmias A.J., Lee F.K. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J Immunol 2005, 174(4):1787-1790.
26. World Health Organization Pneumococcal Serology Reference Laboratories Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA) 2000, World Health Organization, Geneva, Switzerland, http://www.vaccine.uab.edu/ELISA%20Protocol.pdf.
27. Chen M., Hisatomi Y., Furumoto A., Kawakami K., Masaki H., Nagatake T., et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007, 14(2):139-145.
28. Rubins J.B., Puri A.K., Loch J., Charboneau D., MacDonald R., Opstad N., et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998, 178(2):431-440.
29. Törling J., Hedlund J., Konradsen H.B., Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22(1):96-103.
30. Lee P.T., Benlagha K., Teyton L., Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002, 195(5):637-641.
31. Kim C.H., Johnston B., Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Valpha 24(+)Vbeta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002, 100(1):11-16.
32. Thomas S.Y., Hou R., Boyson J.E., Means T.K., Hess C., Olson D.P., et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 2003, 171(5):2571-2580.
33. Galli G., Nuti S., Tavarini S., Galli-Stampino L., De Lalla C., Casorati G., et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003, 197(8):1051-1057.
34. Burdin N., Brossay L., Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999, 29(6):2014-2025.